These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33705497)

  • 1. Clostridioides difficile biofilms: A mechanism of persistence in the gut?
    Frost LR; Cheng JKJ; Unnikrishnan M
    PLoS Pathog; 2021 Mar; 17(3):e1009348. PubMed ID: 33705497
    [No Abstract]   [Full Text] [Related]  

  • 2. Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection.
    Normington C; Moura IB; Bryant JA; Ewin DJ; Clark EV; Kettle MJ; Harris HC; Spittal W; Davis G; Henn MR; Ford CB; Wilcox MH; Buckley AM
    NPJ Biofilms Microbiomes; 2021 Feb; 7(1):16. PubMed ID: 33547298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.
    Baines SD; Freeman J; Wilcox MH
    Antimicrob Agents Chemother; 2009 May; 53(5):2202-4. PubMed ID: 19223641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection.
    Theriot CM; Young VB
    Gut Microbes; 2014; 5(1):86-95. PubMed ID: 24335555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of the gut microbiota during the Clostridioides difficile infection in tree shrews mimics those in humans.
    Gu W; Li W; Wang W; Kuang D; Zhang W; Lu C; Li N; Tong P; Han Y; Sun X; Lu J; Wu Y; Dai J
    BMC Microbiol; 2020 Aug; 20(1):260. PubMed ID: 32819295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile.
    Hamada M; Yamaguchi T; Ishii Y; Chono K; Tateda K
    J Infect Chemother; 2020 Jul; 26(7):685-692. PubMed ID: 32224190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clostridium difficile: the increasingly difficult pathogen.
    Pop-Vicas A; Neill MA
    Crit Care; 2008; 12(1):114. PubMed ID: 18304376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection.
    Abutaleb NS; Seleem MN
    Sci Rep; 2020 May; 10(1):7701. PubMed ID: 32382070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cytotoxic synergy between Clostridioides difficile toxin B and proinflammatory cytokines: an unholy alliance favoring the onset of Clostridioides difficile infection and relapses.
    Bassotti G; Marchegiani A; Marconi P; Fettucciari K
    Microbiologyopen; 2020 Aug; 9(8):e1061. PubMed ID: 32657021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring the impact of Clostridium difficile Infection with the NAP1 strain on severity and mortality.
    Rao K
    Clin Infect Dis; 2014 Oct; 59(8):1193-4. PubMed ID: 24982035
    [No Abstract]   [Full Text] [Related]  

  • 11. Investigation of the effect of the adsorbent DAV131A on the propensity of moxifloxacin to induce simulated Clostridioides (Clostridium) difficile infection (CDI) in an in vitro human gut model.
    Chilton CH; Crowther GS; Miossec C; de Gunzburg J; Andremont A; Wilcox MH
    J Antimicrob Chemother; 2020 Jun; 75(6):1458-1465. PubMed ID: 32097465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The blueprint for building a biofilm the Clostridioides difficile way.
    Tremblay YD; Dupuy B
    Curr Opin Microbiol; 2022 Apr; 66():39-45. PubMed ID: 34933207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial commentary: Host-pathogen interactions in Clostridium difficile infection: it takes two to tango.
    Aronoff DM
    Clin Infect Dis; 2014 May; 58(10):1401-3. PubMed ID: 24604896
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel and emerging sources of Clostridioides difficile infection.
    Turner NA; Smith BA; Lewis SS
    PLoS Pathog; 2019 Dec; 15(12):e1008125. PubMed ID: 31856240
    [No Abstract]   [Full Text] [Related]  

  • 15. Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile.
    Phanchana M; Phetruen T; Harnvoravongchai P; Raksat P; Ounjai P; Chankhamhaengdecha S; Janvilisri T
    Sci Rep; 2020 Apr; 10(1):6497. PubMed ID: 32300130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.
    Tijerina-Rodríguez L; Villarreal-Treviño L; Baines SD; Morfín-Otero R; Camacho-Ortíz A; Flores-Treviño S; Maldonado-Garza H; Rodríguez-Noriega E; Garza-González E
    PLoS One; 2019; 14(7):e0220671. PubMed ID: 31365590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygen response and tolerance mechanisms in Clostridioides difficile.
    Kint N; Morvan C; Martin-Verstraete I
    Curr Opin Microbiol; 2022 Feb; 65():175-182. PubMed ID: 34896836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbe-microbe interactions during Clostridioides difficile infection.
    Abbas A; Zackular JP
    Curr Opin Microbiol; 2020 Feb; 53():19-25. PubMed ID: 32088581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A contemporary review of Clostridioides difficile infections in patients with haematologic diseases.
    Dutta D; Jafri F; Stuhr D; Knoll BM; Lim SH
    J Intern Med; 2021 Mar; 289(3):293-308. PubMed ID: 32910532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmid Acquisition Alters Vancomycin Susceptibility in Clostridioides difficile.
    Pu M; Cho JM; Cunningham SA; Behera GK; Becker S; Amjad T; Greenwood-Quaintance KE; Mendes-Soares H; Jones-Hall Y; Jeraldo PR; Chen J; Dunny G; Patel R; Kashyap PC
    Gastroenterology; 2021 Feb; 160(3):941-945.e8. PubMed ID: 33197449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.